公开(公告)号：US20230192681A1

公开(公告)日：2023-06-22

申请号：US17776948

申请日：2020-11-13

Applicant: AMGEN INC.

Inventor： Andrew T. PARSONS ,  Matthew BEAVER

IPC: C07D471/04 ,  C07F5/05

CPC classification number: C07D471/04 ,  C07F5/05

Abstract: The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

公开(公告)号：US20210284617A1

公开(公告)日：2021-09-16

申请号：US16327079

申请日：2017-08-03

Applicant: Amgen Inc.

Inventor： Matthew BEAVER ,  Sheng CUI ,  Xiangqing SHI

IPC: C07D301/12 ,  B01J31/16

Abstract: The present invention provides new methods for preparing compound 5, and pharmaceutically acceptable salts thereof, of structure Compound 5, or a pharmaceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese catalyst that may be used in the epoxidation step of the present invention.